Metrics on Covid-19: Highlights of the
Evaluate Vantage Report
We can always depend on Evaluate Vantage to keep us current on developments
across the industry. Here are highlights from their most recent report, a compendium
of articles on all aspects of how the coronavirus is impacting healthcare, and by
extension all of us who depend on the professionals fighting this disease.
The coronavirus pandemic haschanged the focus for all of healthcare. Johnson & Johnson, the firstbig pharma company to report firstquarter earnings, said its pharmaceutical and consumer healthunits had a strong start to the yearas patients and medical suppliersstocked up, fearing supply issues.But it was a different story inmedtech, where non-urgent jointreplacement procedures have beenhit hard, and could fall by as muchas 80% in the second quarter.
Similarly, when looking at industry
data on M&A activity or venture
investing, little slowdown can be
seen in the first quarter data. Deals
were struck in the opening months
of the year, but these had probably
already been in progress when the
virus struck; it is hard to imagine
even the most motivated buyer ini-
tiating large and complex transac-
tions while in lockdown.
Venture funds are flush with cash
and remain motivated to fund
start-ups, which will perhaps
shield this particular sector; IPOs
have also held up remarkably
well considering the stock market
meltdown. But no activity can
remain unaffected by a protracted
disruption, and estimates of when
the world might return to normal
are little more than guesses. Some
modeling studies have suggested
that periods of lockdown might be
required until 2022.
An effective treatment or vaccinewould be a game changer, andmany in biopharma are in pursuitof this goal. Collaborations between industry, academia and not-for-profits have emerged at pace: avaccines tie-up between Sanofi andGlaxosmithkline is a remarkableexample of global rivals joining